spacer
home > pmps > summer 2008 > dosage dilemmas
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Dosage Dilemmas

AN IMPRECISE SCIENCE

Ensuring the correct dosage of milligram amounts of powders into capsules has traditionally been a difficult and imprecise science for pharmaceutical companies, particularly as the material is significantly lighter than the weight of the capsule shell.

Administration of minute amounts of drugs into hard gelatine capsules, for instance, can be problematic due to the forces of agglomeration and cohesion, resulting in a poor flow which could cause the weight of the dose to fluctuate between 15 and 20 per cent – an unacceptable condition when handling pharmaceutical products.

ADVANCING AUTOMATION

In the search for a process which can automatically provide accurate and precise weight measurements for dispensing microdoses of powder into capsules, significant advances have been made. Until now, this process has mostly been carried out on standard automatic machines that have been adapted with dosing mechanisms to handle such small quantities of powder, but because capsules were not weighed prior to filling, it was impossible to make reliable estimations as to the weight of the capsule’s content.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Robin Davies is Managing Director of Isopak Ltd, a leading UK supplier of equipment to the pharmaceutical, healthcare industries and also exclusive distributor in the UK of Italy-based MG2’s quality range of machines. Before starting Isopak, Robin ran Stamford Packaging, before becoming the Sales Manager for CAM, a major Italian packaging machine manufacturer. He has also been Chief Engineer for a company called Peter Holland, a distributor for a range of manufacturers of packaging.
spacer
Robin Davies
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement